Indegene completes merger of German indirect wholly owned subsidiaries
As filed · Indegene Limited has informed the Exchange about Amalgamation/Merger of Indirect Wholly Owned Subsidiaries of the Company in Germany
What happened
FactIndegene Healthcare Germany GmbH merged into Trilogy Writing & Consulting GmbH, effective September 9, 2026, following registration in Frankfurt. Trilogy survived the merger, changed its name to Indegene Healthcare Germany GmbH, and will operate under that name.
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedOur Q4 adjusted EBITDA came in at ₹1,889 million, growing 23.2% year-over-year.
The full year adjusted EBITDA totalled ₹6,793 million, up 20.8% year-on-year.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- Reflecting this strength, the Board has recommended a final dividend of ₹2.25 per share - a 12.5% increase ove (management committed by FY26)
- With a strong pipeline and an industry-leading revenue per employee of $75k, we will build on this momentum in (management committed by FY27)
Evidence
- Indegene Limited has informed the Exchange about Amalgamation/Merger of Indirect Wholly Owned Subsidiaries of the Company in Germany(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
- Earlier statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- The transaction consolidates Indegene's German healthcare and life-sciences services operations under one entity. The company said it is an internal restructuring with no material impact on its business operations, shareholding pattern, or financial position.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%